Announcements - OBI Pharma 台灣浩鼎

2018.Dec.03

OBI Pharma Inc. to attend the Citi's 2018 Global Healthcare Conference

2018.Nov.30

Announcement of the resolution of the board of directors of the company to issue common shares through rights offering

2018.Nov.23

OBI Pharma Inc. to attend the 2018 Asia Pacific Healthcare Forum, hosted by Goldman Sachs

2018.Nov.23

Clarification on the news article by Up Media and other media groups

2018.Nov.21

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

2018.Nov.15

Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong

2018.Nov.12

Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase

2018.Nov.02

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States

2018.Oct.29

OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia

2018.Oct.01

OBI received notice from patent attorney’s office that product patent for OBI-822 named "Compound and Compositions of Carbohydrate Vaccine and Uses Thereof" has been approved by Taiwan Intellectual Property Office

News

Latest News

Events

Latest events